article

Retatrutide Titration Schedule 2026: Starting Dose to 12mg

Retatrutide titration schedule from the Phase 2 trial: 2mg starting dose escalating to 12mg every 4 weeks, plus a 6-week slow protocol for nausea-prone users. Includes dose-step failure guidance.

Weekly injection planner calendar with retatrutide vial and syringe on white clinical surface

Retatrutide Titration

Retatrutide Titration Schedule: Phase 2 Standard and Slow Protocol

The retatrutide titration schedule from the Phase 2 trial escalates from 2mg to 4mg to 8mg to 12mg, every 4 weeks (Jastreboff et al., NEJM 2023). For nausea-prone users, a conservative 6-week interval variant extends that timeline so the maintenance dose begins at approximately week 19. This guide covers both calendars, dose-step failure recovery, and how to know when you're ready to escalate. For full background on the compound, the complete retatrutide guide is a good starting point.

Key Takeaways

  • Standard retatrutide titration schedule: 2mg (weeks 1-4) to 4mg (weeks 5-8) to 8mg (weeks 9-12) to 12mg maintenance, per the Phase 2 trial (Jastreboff et al., NEJM 2023).
  • 4-week minimum interval between dose increases aligns with the 4-5 week time needed to reach steady-state plasma concentration at each dose level.
  • Slow-titration variant extends each phase to 6 weeks, reaching 12mg at approximately week 19 instead of week 13.
  • GI side effects rise with dose: in the Phase 2 trial, nausea affected 45 percent of the 12mg group versus 11 percent on placebo, and starting at 2mg instead of 4mg cut nausea in the 8mg group from 60 to 17 percent, making careful titration essential.
  • If a dose increase causes intolerable GI symptoms, the Phase 2 protocol explicitly permitted returning to the prior dose level and waiting a full 4 weeks before re-attempting escalation.
  • Retatrutide is investigational and not FDA-approved. Always work with a licensed prescriber.

4 weeks

Minimum interval between dose increases

2mg to 12mg

Phase 2 dose range (Jastreboff 2023)

~12 weeks

Time to reach 12mg on standard protocol

24.2%

Weight loss at 12mg, 48 weeks (Phase 2)

Investigational Drug Warning

Retatrutide (LY3437943) is not FDA-approved as of October 2026. Phase 3 results from Eli Lilly's TRIUMPH program have been reported, and Lilly plans to file for FDA approval in Q1 2027. All dosing and titration information here is derived from the published Phase 2 trial (Jastreboff et al., NEJM 2023) and is for educational purposes only. Do not start, stop, or modify any medication without working with a prescriber.

What Is a Retatrutide Titration Schedule?

Titration means starting at a low dose and increasing gradually over time, rather than starting at the target dose immediately. For retatrutide, this process is especially important because of its triple-receptor mechanism. Where semaglutide activates one receptor (GLP-1) and tirzepatide activates two (GLP-1 and GIP), retatrutide adds glucagon receptor agonism. That glucagon component significantly increases energy expenditure and fat oxidation, but also drives higher GI side effect rates at elevated doses. A proper retatrutide titration schedule manages that tradeoff systematically. This article covers the dose-by-dose escalation calendar; for the broader retatrutide dosing schedule framework see the sibling guide, and for full clinical background the full retatrutide dosing guide.

Why Titration Matters More for Retatrutide Than Other GLP-1s

In the Phase 2 trial (Jastreboff et al., NEJM 2023; adverse-event results posted on ClinicalTrials.gov), GI adverse events were the most common side effects and rose with dose: nausea affected 45 percent of the 12mg group versus 11 percent on placebo, with vomiting at 19 percent and diarrhea at 15 percent. The starting dose made a large difference. In the 8mg group, nausea hit 60 percent when the dose started at 4mg and 17 percent when it started at 2mg. The 4-week titration interval is not arbitrary: retatrutide takes approximately 4 to 5 weeks to reach steady-state plasma concentration at each dose level, given its half-life of approximately 6 days. Escalating before steady state means escalating before you have seen the full effect of your current dose. For the pharmacokinetic explanation behind this interval, the retatrutide half-life guide covers why 4-week intervals are grounded in the drug's PK profile.

Retatrutide Titration Schedule: Standard Phase 2 Protocol

The table below reflects the Phase 2 trial protocol for the primary escalation arm (Jastreboff et al., NEJM 2023). This is the evidence-grounded retatrutide titration schedule most prescribers reference.

Week-by-Week Calendar: Standard 4-Week Protocol

Phase Weeks Dose Notes
Initiation 1-4 2mg once weekly GI symptoms typically peak in days 3-5 post-injection. Most subside within the first 2 weeks. Some clinicians use 1mg or 0.5mg as a pre-titration step before starting the Phase 2 protocol.
First escalation 5-8 4mg once weekly Increase only if 2mg was well tolerated for the full 4 weeks. GI symptoms may resurface briefly at the new dose level.
Second escalation 9-12 8mg once weekly Significant efficacy increase. GI adverse event rates climb at this dose level. Tolerance improves over the 4-week phase for most users.
Maintenance 13+ 12mg once weekly Maximum dose tested in Phase 2. The 12mg arm produced 24.2% body weight loss at 48 weeks (Jastreboff et al., NEJM 2023). Not all users need or tolerate 12mg; 8mg is a clinically meaningful alternative maintenance dose.

Phase 2 starting dose note

The Phase 2 trial minimum active arm used 2mg as the starting dose. In clinical practice, some prescribers begin at 1mg or even 0.5mg as a pre-titration step before entering the 2mg phase, particularly for patients with a history of GI sensitivity on GLP-1 medications. This practice is not contradicted by the trial data; the trial set 2mg as the lowest active arm, not as an absolute minimum starting point.

What "Well Tolerated" Means Before Escalating

Before moving to the next dose in your retatrutide titration schedule, the current dose should be well tolerated. In practice, this means:

  • No persistent nausea or vomiting for at least 7 consecutive days at the end of the current phase
  • No ongoing diarrhea or significant GI discomfort that impacts daily functioning
  • You are in week 4 or later at the current dose level (the 4-week minimum is absolute)

If any of those conditions are not met at week 4, you are not ready to escalate. Continue at the current dose until the tolerability window clears, then proceed. This is not a failure; it is the protocol working as intended.

Map your exact titration timeline

The GLP3Planner retatrutide calculator models your dose curve, shows plasma level estimates at each phase, and automatically flags your next dose-day.

Open Retatrutide Calculator
Step pyramid chart showing retatrutide dose escalation from 2mg to 4mg to 8mg to 12mg with week ranges for each

Retatrutide dose escalation chart: four phases increasing every 4 weeks from 2mg to 12mg. Based on the Phase 2 trial protocol (Jastreboff et al., NEJM 2023).

Slow-Titration Protocol: Conservative Escalation for Nausea-Prone Users

The Phase 2 trial protocol explicitly allowed prescribers to delay or skip dose escalation at physician discretion for participants who did not tolerate the protocol-specified increase (Jastreboff et al., NEJM 2023, Supplementary Appendix). This allowance is the clinical basis for the slow-titration approach: extending each dose phase from 4 weeks to 6 weeks to give the body additional time to adapt before escalation.

The 6-week variant is not a separately named protocol with its own trial arm. It is a permitted modification. The tradeoff is straightforward: better tolerability at the cost of a longer ramp-up timeline, reaching 12mg at approximately week 19 rather than week 13.

Extended 6-Week Protocol Calendar

Phase Weeks Dose vs Standard
Initiation 1-6 2mg once weekly +2 weeks vs standard
First escalation 7-12 4mg once weekly +2 weeks vs standard
Second escalation 13-18 8mg once weekly +2 weeks vs standard
Maintenance 19+ 12mg once weekly Reaches max dose at ~week 19 vs week 13 on standard

Who Should Consider Slow Titration?

Whether to use a standard or extended titration interval is a call for your prescriber to make. These are the factors that typically point toward the slower path:

  • Prior intolerable nausea or vomiting on semaglutide, tirzepatide, or other GLP-1 medications
  • History of GERD, gastroparesis, or functional GI disorders
  • Lower body weight, where the effective dose-per-kilogram is relatively higher at standard doses
  • First-time users of peptide or GLP-class medications with no tolerability baseline

The slow-titration approach does not change the target dose or the expected outcomes. It only changes the timeline. If you manage GI symptoms fine on the standard 4-week protocol, there's no reason to extend. Either way, this is a conversation to have with whoever is managing your prescription.

What to Do If a Dose Increase Causes Intolerable Side Effects

Persistent nausea or vomiting after a dose increase is common and does not mean the medication is wrong for you. The Phase 2 protocol explicitly allowed dose escalation to be skipped or delayed when tolerability criteria were not met (Jastreboff et al., NEJM 2023). Participants who could not tolerate escalation remained at the highest tolerated dose for the remainder of the treatment period. You have three practical options when a dose increase fails:

Option 1: Stay at the current dose for another full cycle

Remain at the new dose for an additional 4 weeks, or up to 6 weeks on the slow-titration protocol. GI adaptation often continues into the second month at a given dose level. If symptoms resolve, continue. If not, move to Option 2.

Option 2: Return to the prior dose level

If symptoms (persistent nausea or vomiting lasting more than 7 days) are intolerable at the new dose, return to the prior dose level. Remain there for a full 4 weeks, then re-attempt escalation. This is the approach explicitly permitted in the Phase 2 protocol. Source: Jastreboff AM et al., NEJM 2023, supplementary methods.

Option 3: Accept a lower maintenance dose

If 12mg is persistently intolerable after repeated attempts, 8mg is a clinically reasonable maintenance dose. Phase 2 data showed clinically significant weight loss across all dose arms above 4mg. Remaining at 8mg long-term is a legitimate outcome, not a failure. Discuss this with your prescriber.

You are not failing the medication

The Phase 2 protocol allowed dose escalation to be skipped or delayed at physician discretion. Finding your tolerable maintenance dose, whether that is 8mg or 12mg, is the goal of titration. The retatrutide titration schedule is a framework, not a rigid requirement.

For a full breakdown of GI and other adverse effects, the retatrutide side effects guide covers management strategies dose by dose.

How to Know When to Escalate Your Dose

Track your symptoms week by week and the escalation decision usually answers itself. Signs you're ready to move to the next dose:

  • GI symptoms (nausea, vomiting, diarrhea) have resolved or are minimal for at least 7 consecutive days
  • Appetite suppression remains noticeable but you sense a plateau effect developing at the current dose
  • You have completed at least 4 full weeks at the current dose level
  • You have no significant intercurrent illness that might confuse attribution of new symptoms

Signs to wait:

  • Ongoing nausea or vomiting, even if mild, at the end of the current dose phase
  • A recent GI illness (unrelated to the medication) that makes it hard to attribute current symptoms
  • A major life stressor or schedule disruption that might amplify side effects
  • Fewer than 4 weeks at the current dose, regardless of how you feel

When in doubt, an additional week at the current dose costs very little. Rushing escalation when symptoms are still present risks a step backward.

Two parallel retatrutide titration timelines: standard 4-week protocol reaches 12mg at week 13 versus slow 6-week protocol at week 19

Standard versus slow retatrutide titration protocol: both reach 12mg, but the 6-week conservative path takes approximately 6 additional weeks. Neither protocol changes the target dose.

Video: Retatrutide Dosing and Clinical Trial Results Explained

Alex Wallace covers retatrutide dosing, Phase 2 clinical trial data, and weight loss results. This educational video does not represent medical advice.

Using the GLP3Planner Calculator for Your Titration Schedule

The retatrutide calculator at GLP3Planner lets you model your exact titration timeline: enter your starting dose, escalation interval, and planned dose increases, and the tool generates a dose curve showing estimated plasma concentration at each phase. You can also see when each 4-week or 6-week window opens, plan your injection days, and share your schedule via a token link. It uses pharmacokinetic exponential decay modeling based on the published 6-day half-life data.

Build your retatrutide schedule

Model standard or slow-titration timelines, see plasma level curves, and track your dose-day schedule. Free, no account required.

Open Retatrutide Calculator

Frequently Asked Questions

What is the standard retatrutide titration schedule?

The Phase 2 trial protocol titrates retatrutide from 2mg to 4mg to 8mg to 12mg, increasing every 4 weeks. Each dose level is maintained for a full 4 weeks to allow the body to reach steady-state plasma concentration before escalating. The maximum dose tested in Phase 2 was 12mg once weekly, where 24.2% body weight loss was recorded at 48 weeks (Jastreboff et al., NEJM 2023).

How fast can I titrate retatrutide?

The minimum titration interval in the Phase 2 protocol was 4 weeks between dose increases. Escalating faster has not been studied and is likely to produce intolerable GI side effects, since retatrutide takes approximately 4 to 5 weeks to reach steady-state plasma concentration at each dose level given its roughly 6-day half-life. The retatrutide half-life guide explains the pharmacokinetic rationale in detail.

Does retatrutide need to be titrated?

Yes. Retatrutide's GI side effects are dose-dependent: in the Phase 2 trial, nausea affected 45 percent of the 12mg group versus 11 percent on placebo, and the trial authors reported that a lower starting dose (2mg vs. 4mg) partially mitigated GI events. Starting at a lower dose and titrating gradually allows the GI system to adapt. Starting higher made a measurable difference: in the Phase 2 4mg groups, nausea affected 36% of those who started directly at 4mg versus 18% of those who began at 2mg. Starting directly at 8mg or 12mg has not been studied.

What to expect in the first week of retatrutide?

In the first week at 2mg, most users notice mild appetite suppression and possibly mild nausea or fatigue. These effects typically peak in days 3-5 post-injection and subside as the body adapts. GI symptoms are most pronounced with each dose increase and tend to ease within 7-10 days of the new dose level. Your first week is part of the tolerability ramp, not a preview of the full maintenance experience.

Is 2mg of retatrutide enough to produce results?

2mg is the Phase 2 starting dose and produces clinically meaningful appetite suppression for most users. However, it is not the target maintenance dose. Significant weight loss outcomes in Phase 2 (up to 24.2% at 12mg over 48 weeks) were recorded at higher doses. The 2mg initiation phase is a tolerability ramp, not the end goal. Most users notice clear efficacy changes once they reach 8mg or above.

How many weeks does it take for retatrutide to reach full effect?

On the standard 4-week titration protocol, reaching the 12mg maintenance dose takes approximately 12 weeks. Full clinical effect at the maintenance dose develops over subsequent weeks as the drug reaches steady state. Phase 2 measured outcomes at 48 weeks total, meaning meaningful weight loss continues well beyond the titration period. The titration phase itself is a small fraction of the total treatment arc.

What should I do if I cannot tolerate my current retatrutide dose?

Do not attempt to escalate further. Stay at the current dose for an additional 2-4 weeks, or return to the prior dose level if symptoms are severe. The Phase 2 protocol explicitly allowed dose escalation delays and step-backs. Many users find their tolerable maintenance dose is 8mg rather than 12mg, and clinically significant weight loss was observed across all dose arms above 4mg. Always consult your prescriber before changing your dose.

Why are retatrutide dose increases every 4 weeks instead of every 2 weeks?

Retatrutide has a half-life of approximately 6 days, meaning it takes 4 to 5 weeks to reach steady state at any given dose. Escalating before steady state means escalating before you have seen the full effect of your current dose, which risks side effects from a drug level that is still rising. The 4-week interval is pharmacokinetically grounded in the drug's biology. See the retatrutide half-life guide for the full explanation.

Can I stay at a lower maintenance dose permanently?

Yes. While Phase 2 trials tested escalation to 12mg as the maximum dose, individual maintenance doses vary by tolerance and response. If 8mg produces good weight loss results with acceptable tolerability, remaining at that dose is a clinically reasonable outcome. This is a discussion for your prescribing clinician based on your response profile and personal tolerability.

Ready to map your titration schedule?

The GLP3Planner retatrutide calculator visualizes your dose curve and flags your next dose day automatically. Free to use, no account required.

Open Retatrutide Calculator

Peer-Reviewed Sources

  1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity -- A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
  2. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022;35(10):1846-1860. https://doi.org/10.1016/j.cmet.2022.09.009
  3. ClinicalTrials.gov. TRIUMPH-1 (NCT05929066): A Study of Retatrutide in Adults With Obesity or Overweight (Phase 3). National Library of Medicine. https://clinicaltrials.gov/study/NCT05929066
  4. U.S. Food and Drug Administration. Investigational New Drug (IND) Application Overview. FDA.gov. https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application
  5. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021;385(6):503-515. https://www.nejm.org/doi/full/10.1056/NEJMoa2107250
  6. ClinicalTrials.gov. A Study of LY3437943 in Participants Who Have Obesity or Overweight (NCT04881760). Posted results, adverse events. National Library of Medicine. https://clinicaltrials.gov/study/NCT04881760?tab=results

Medical Disclaimer

Retatrutide (LY3437943) is an investigational drug and is not approved by the U.S. Food and Drug Administration as of October 2026. All dosing, titration, and pharmacokinetic information in this article is derived from published clinical trial data and is provided for educational purposes only. This content is not medical advice and should not be used as a substitute for guidance from a qualified prescriber. Always consult a physician or pharmacist before starting, stopping, or changing any medication.

Related Retatrutide Guides